Pathfinder Cell Therapy (Pathfinder Cell Therapy) Debt-to-Asset : 138.80 (As of Sep. 2015)

Pathfinder Cell Therapy Debt-to-Asset Chart

Pathfinder Cell Therapy Annual Data
	Trend	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14
Debt-to-Asset		Get a 7-Day Free Trial					5.12	0.49	6.33	25.74	47.01

Pathfinder Cell Therapy Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
Debt-to-Asset	Get a 7-Day Free Trial															68.63	47.01	59.93	106.76	138.80

Competitive Comparison of Pathfinder Cell Therapy's Debt-to-Asset

For the Biotechnology subindustry, Pathfinder Cell Therapy's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pathfinder Cell Therapy's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Debt-to-Asset falls into.

Pathfinder Cell Therapy Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pathfinder Cell Therapy's Debt-to-Asset for the fiscal year that ended in Dec. 2014 is calculated as

Pathfinder Cell Therapy's Debt-to-Asset for the quarter that ended in Sep. 2015 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pathfinder Cell Therapy  (OTCPK:PFND) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pathfinder Cell Therapy Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description